Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNittayananta W.
dc.contributor.authorKemapunmanus M.
dc.contributor.authorYangngam S.
dc.contributor.authorTalungchit S.
dc.contributor.authorSriplung H.
dc.description.abstractBackground: The objectives of this study were to determine (i) the expression of oral secretory leukocyte protease inhibitor (SLPI) in HIV-infected subjects compared with non-HIV controls, (ii) the oral SLPI expression in HIV-infected subjects with antiretroviral therapy (ART) compared with those without ART, and (iii) factors associated with the expression of oral SLPI. Methods: Oral tissues and samples of both un-stimulated and stimulated saliva were collected from HIV-infected subjects with and without ART, and non-HIV individuals. The expression of SLPI mRNA in the tissue was determined by quantitative real-time PCR. Salivary SLPI protein was detected using ELISA. Chi-square test and logistic regression analysis were performed to determine the association between HIV/ART status and the expression of oral SLPI. Results: One hundred and fifty-seven HIV-infected subjects were enrolled: 99 on ART (age range, 23-57 years; mean, 39 years), 58 not on ART (age range, 20-59 years; mean, 34 years), and 50 non-HIV controls (age range, 19-59 years; mean, 36 years). The most common ART regimen was 2NRTIs + 1NNRTI. The expression of oral SLPI in stimulated saliva was significantly decreased with HIV infection (P < 0.001). The expression was also significantly different with respect to ART use (P = 0.007). Smoking, CD4+ cell count, and HIV viral load were the factors associated with the oral SLPI expression. Conclusion: The expression of oral SLPI is altered by HIV infection and use of ART. Thus, oral SLPI may be the useful biomarker to identify subjects at risk of infections and malignant transformation due to HIV infection and long-term ART.© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.
dc.subjectantiretrovirus agent
dc.subjectmessenger RNA
dc.subjectnonnucleoside reverse transcriptase inhibitor
dc.subjectproteinase inhibitor
dc.subjectRNA directed DNA polymerase inhibitor
dc.subjectsecretory leukocyte proteinase inhibitor
dc.subjectCD4 lymphocyte count
dc.subjectcontrolled study
dc.subjectenzyme linked immunosorbent assay
dc.subjectHuman immunodeficiency virus
dc.subjectHuman immunodeficiency virus infection
dc.subjectinnate immunity
dc.subjectmajor clinical study
dc.subjectpriority journal
dc.subjectprotein expression
dc.subjectreal time polymerase chain reaction
dc.subjectvirus load
dc.subjectAlcohol Drinking
dc.subjectAnti-HIV Agents
dc.subjectAnti-Retroviral Agents
dc.subjectBiological Markers
dc.subjectCD4 Lymphocyte Count
dc.subjectCross-Sectional Studies
dc.subjectGingival Hemorrhage
dc.subjectHIV Infections
dc.subjectMiddle Aged
dc.subjectMouth Mucosa
dc.subjectOral Health
dc.subjectPeriodontal Pocket
dc.subjectSalivary Proteins and Peptides
dc.subjectSecretory Leukocyte Peptidase Inhibitor
dc.subjectSecretory Rate
dc.subjectSerine Proteinase Inhibitors
dc.subjectTime Factors
dc.subjectViral Load
dc.subjectYoung Adult
dc.titleExpression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy
dc.identifier.bibliograpycitationJournal of Oral Pathology and Medicine. Vol 42, No.3 (2013), p.208-215
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.

Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.